Covalon Technologies Ltd (COV) Fair Value & Analysis
Healthcare · CA · Market cap A$70.6M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −15.2% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.3315 – A$0.8559 · fair‑value band A$0.1400 – A$0.2400 · the A$0.4700 price screens above the A$0.1900 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Covalon Technologies Ltd (COV) currently trades at A$0.4700, while our model-based Fair Value estimate is A$0.1900 — implying the stock looks roughly 59.6% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$2.6M. It earns a return on equity of -49.6%. Net debt stands at A$1.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre- and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers a medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chai…
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Covalon Technologies Ltd reported revenue of A$1.2M in FY2025 versus A$0 in FY2022. Reported net income was −A$4.0M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Covalon Technologies Ltd (COV) undervalued?
What is the fair value of COV?
What is the quality score of COV?
What is the revenue of Covalon Technologies Ltd (COV)?
What is the net profit margin of COV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.